Skip to main content
. 2022 Dec 28;12(1):231. doi: 10.3390/jcm12010231

Figure 2.

Figure 2

(A) Cumulative incidence of HBV reactivation in HBsAg-positive patients without prophylactic NUC who received chemotherapy or tyrosine kinase inhibitor (TKI). (B) Comparison of cumulative HBV-related hepatitis incidence between HBsAg-positive patients without prophylactic NUC receiving chemotherapy and TKI. (C) Comparison of cumulative HBV reactivation incidence in patients receiving first-line TKI without prophylactic NUC between HBsAg-positive and HBsAg-negative groups. TKI, tyrosine kinase inhibitor.